Latest news and insights on the pharmaceutical industry | Indian Pharma Post

Results For "toxicokinetic"

2 News Found

Quantum BioPharma completes key toxicity studies for Lucid-MS, paving way for Phase 2 MS trial
Clinical Trials | December 29, 2025

Quantum BioPharma completes key toxicity studies for Lucid-MS, paving way for Phase 2 MS trial

Lucid-MS represents a potential breakthrough in the treatment of multiple sclerosis

Vivo Bio Tech enters long-term contract with Bio E
Biotech | August 30, 2021

Vivo Bio Tech enters long-term contract with Bio E

The value of the contract is estimated to be between Rs 20-30 crores per year for the next three years

Latest Stories

Next Gen Diagnostics to spin off infection prevention unit

Quantum BioPharma completes key toxicity studies for Lucid-MS, paving way for Phase 2 MS trial

SN Bioscience’s SNB-101 wins FDA orphan drug designation for gastric cancer

White Papers

Chasing Consistency: Centralizing operations data is the key to optimizing chemicals plants

Implementing a digital transformation in chemical operations to maximize profitability

The complexity of compliance

The Sprint to the Summit: Unlocking Lab Efficiency through Digital Transformation

The guiding role of fluidized and spouted bed technologies in particle building processes

Interviews
Only 4-5 Indian pharma companies have a strong presence in Russia, opportunity is far bigger now: Manish Kumar, Vice-Chairman, Moscow Chamber of Commerce, Indian Commission; and President, Soltex Group
Only 4-5 Indian pharma companies have a strong presence in Russia, opportunity is far bigger now: Manish Kumar, Vice-Chairman, Moscow Chamber of Commerce, Indian Commission; and President, Soltex Group
Only 4-5 Indian pharma companies have a strong presence in Russia but the opportunity is far bigger now: Manish Kumar, Vice-Chairman, Moscow Chamber of Commerce, Indian Commission; and President, Soltex Group
Only 4-5 Indian pharma companies have a strong presence in Russia but the opportunity is far bigger now: Manish Kumar, Vice-Chairman, Moscow Chamber of Commerce, Indian Commission; and President, Soltex Group
Companies must shift from L1 costing to Life Cycle Cost Analysis: Abhilash Pasham, Associate GM - Central Engineering & Projects, Dr. Reddy's Laboratories
Companies must shift from L1 costing to Life Cycle Cost Analysis: Abhilash Pasham, Associate GM - Central Engineering & Projects, Dr. Reddy's Laboratories

Packaging